Current Ozempic prescribing information describes semaglutide as a GLP-1 receptor agonist, while current Mounjaro prescribing information describes tirzepatide as a GIP/GLP-1 receptor agonist. Available products, formulations, indications, and schedules differ, and separate trials do not establish a simple head-to-head winner or a milligram conversion.
If you are comparing Ozempic, Wegovy, Mounjaro, or Zepbound, the most useful question is not simply "Which is stronger?" It is: which medication is approved for your condition, covered by your plan, tolerated by your body, and appropriate for your prescriber's goals?
What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a hormone involved in insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.
In the U.S., semaglutide appears under multiple labels, including Ozempic and Wegovy. The current Ozempic prescribing information and Wegovy prescribing information have different indications, formulations, dose instructions, and missed-dose rules even though both contain semaglutide.
What Tirzepatide Is
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates the GLP-1 pathway and also the glucose-dependent insulinotropic polypeptide pathway. That second mechanism is the reason tirzepatide is often discussed separately from older GLP-1-only medicines.
Tirzepatide is sold as Mounjaro and Zepbound. The current Mounjaro prescribing information and Zepbound prescribing information define different indicated populations and product-specific dose choices even though strengths overlap.
Semaglutide vs. Tirzepatide at a Glance
| Comparison | Semaglutide | Tirzepatide |
|---|---|---|
| Main mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Common U.S. brands | Ozempic, Wegovy | Mounjaro, Zepbound |
| Typical schedule | Depends on the exact semaglutide product and formulation | Once-weekly injection for cited tirzepatide products |
| Dose scale | Varies by product and formulation | Product-specific instructions use listed tirzepatide strengths |
| Milligram conversion | Not interchangeable | Not interchangeable |
| Tracking need | Brand, dose, injection day, side effects | Brand, dose, titration step, side effects |
The key practical point: their milligrams do not compare. A 1 mg semaglutide dose is not equivalent to 1 mg, 2.5 mg, or 5 mg of tirzepatide. They are different molecules with different dosing ladders.
What the Evidence Says — and What It Does Not
Both medications have strong clinical-trial evidence in their labeled populations. Semaglutide 2.4 mg showed substantial average weight loss in the STEP program; for example, the STEP 1 trial was published in the New England Journal of Medicine and indexed on PubMed. Tirzepatide showed substantial average weight loss in the SURMOUNT program; SURMOUNT-1 is also indexed on PubMed.
Those trials are useful only with their specific populations, doses, comparators, and durations attached. They are not head-to-head evidence and do not predict an individual's response.
Do not use separate-trial headline percentages to declare one medication universally “stronger.” A clinician should apply evidence from the relevant indication and population.
Dosing Differences Matter More Than People Realize
Wegovy injection and Mounjaro are titrated gradually under different product-specific schedules. The current Wegovy prescribing information and Mounjaro prescribing information each connect their escalation schedule to reducing gastrointestinal adverse-reaction risk. That does not create a shared schedule for every semaglutide or tirzepatide formulation.
The exact schedules are stated in the current product labels linked above. Not every listed strength is a mandatory step, and current Wegovy instructions depend on formulation.
This is why switching is not a matter of matching numbers. The labels do not provide a universal conversion or transition schedule; your prescriber must specify the product, starting dose, and timing.
Side Effects and Tolerability
The current Ozempic, Wegovy, Mounjaro, and Zepbound labels list product-specific gastrointestinal adverse reactions. Trial frequencies belong to each product, dose, and studied population and should not be converted into a comparative personal prediction.
Individual tolerability cannot be predicted from mechanism alone. Dose and schedule decisions belong with the prescriber and exact product label.
Follow the urgent symptom directions for the exact medicine rather than a class-wide checklist. The MedlinePlus semaglutide injection instructions and MedlinePlus tirzepatide injection instructions provide separate product-specific directions; use emergency services for an emergency.
How to Track Either Medication
Whether you use a semaglutide tracker or a tirzepatide tracker, the basics are similar: log the medication, dose, injection day, injection site, side effects, and outcomes you and your clinician care about. The details matter most during titration and switching, when memory gets unreliable.
OffGrid Dose supports that longitudinal view: semaglutide history, tirzepatide history, injection-site rotation, and dose changes in one private record. The privacy-first GLP-1 tracker. OffGrid Dose does not receive health data or operate company cloud sync. You can review the full feature set, or start with the medication page that matches your prescription.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
Separate semaglutide and tirzepatide trials do not establish a universal winner. Your prescriber should interpret evidence relevant to the exact product, indication, and individual situation.
Can I convert my semaglutide dose to a tirzepatide dose?
No. There is no patient-safe milligram conversion. Semaglutide and tirzepatide are different molecules with different dose ladders, so switching should be prescribed as a clinical transition, not a math problem.
Are Ozempic and Mounjaro the same type of medication?
They are related but not identical. Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist.
Do semaglutide and tirzepatide have the same injection day rules?
They are both once-weekly injections, but the exact missed-dose and day-change instructions differ by product label. Always check the current label for Ozempic, Wegovy, Mounjaro, or Zepbound rather than assuming one rule applies to all.
Which one is easier to tolerate?
There is no reliable answer for everyone. Current labels list gastrointestinal adverse reactions for both. A symptom log can document timing for a prescriber but cannot predict which drug will be easier to tolerate.
This article is for general educational purposes only and is not medical advice. Semaglutide and tirzepatide should be used only under the supervision of a licensed clinician. Do not start, stop, switch, or adjust doses based on a comparison article; follow your prescription label and prescriber's instructions.
Related Articles
Track this with OffGrid Dose
Log every dose, rotate injection sites, and watch your weight trend in a private local working log.
Ozempic tracker →